CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Silo Pharma Partners with Zylo Therapeutics

Life Sciences Review Life Sciences Review | Thursday, May 20, 2021
Tweet

Sustained Transdermal delivery method to become essential for Alzheimers and Parkinsons patients with Dysphagia.


FREMONT, CA: Silo Pharma, a developmental stage biopharmaceutical firm focused on the use of psychedelics as a therapeutic, enters into a Joint Venture with Zylo Therapeutics.  This Joint Venture will utilize Zylos innovative sustained-release topical delivery system developed at Albert Einstein College of Medicine, leveraging Silo Pharma’s expertise in the use of psychedelics. The joint venture will explore the clinical development of ketamine using ZTIs Z-pod technology and offers for Silo Pharma to get an exclusive option for the clinical effect of psilocybin using ZTIs Z-pod technology as well.


Eric Weisblum, CEO of Silo Pharma, stated This Joint Venture is part of Silo Pharma’s vision of bringing therapeutics to patients in need.  The ability to offer Ketamine or Psilocybin in a time-released manner will enable us to explore both the safety and efficacy of the therapeutics while hopefully diminishing the hallucinogenic impacts of psychedelics.  We believe that Zylo’s patented technology will help to reach potential patients that suffer from Dysphagia, like both Alzheimers and Parkinsons patients.


Zylo Therapeutics is exceptionally excited to be entering into this partnership with Silo Pharma, a company with broad-ranging expertise in psychedelics. Ketamine is a versatile drug that continues to show promise with novel therapeutic indications. The company is looking forward to leveraging proprietary topical delivery technology to build a low-dose, sustained-release ketamine formulation that is safe and convenient for patients.


Silo Pharma. is a developmental stage biopharmaceutical organization focused on merging traditional therapeutics with psychedelic research for people suffering from depression, PTSD, Parkinsons, and other rare neurological diseases. Silos mission is to identify assets to license and fund the investigation, which the companies believe will be transformative to the well-being of patients and the health care sector.


Weekly Brief

loading
Top 10 Preeminent Cros – 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/silo-pharma-partners-with-zylo-therapeutics--nwid-366.html